BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Greek Pharmaceutical Market to Show Modest Growth Despite Unstable Economy: GlobalData


10/3/2013 9:58:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, UK (GlobalData), 3 October 2013 - The growing prevalence of chronic diseases and an increasing elderly population will boost the Greek pharmaceutical market, which will increase from approximately $7.8 billion in 2013 to $8.2 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 0.6%, forecasts research and consulting firm GlobalData.

According to the company’s latest report*, the Greek pharmaceutical market was valued at $7.5 billion in 2007; but, following the recent economic crisis, net public pharmaceutical expenditure saw a cumulative decline of $1.67 billion. This decline was due to amendments made to medicine prices, as well as changes to the reimbursement rates for Social Security Funds (SSFs) and to the regulation of wholesale and retail margins.

The medical device sector will also experience modest growth, from $907m in 2007 to $1.2 billion in 2020, at a CAGR of 2.7%. The major segments in 2012 were In Vitro Diagnostics (IVD) (20.8%), cardiovascular devices (11.6%), ophthalmic devices (9.7%), drug delivery devices (7.6%), and diagnostic imaging (7.4%).

Joshua Owide, Director of Healthcare Industry Dynamics, says: “As part of cost-containment measures, the Greek government is encouraging the use of generics with the aim that generics will eventually account for 50% of all medicines used in hospitals. As part of the economic reforms and austerity measures, nearly 95% of drug prices have been reduced by 20%.

“Furthermore, healthcare reforms in terms of reimbursement have led to an increase in the co-payments for certain chronic diseases, with rates ranging from 10% to 25%. These, along with other cost-containment measures, will restrict market growth.”

However, the Greek government has introduced several policies in order to strengthen its free healthcare system and help improve patients’ health outcomes and quality of life in the long run.

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece

This report provides information and analysis on the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@globaldata.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES